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Background
Allopurinol, a commonly prescribed medication for gout
and hyperuricemia, is a frequent cause of severe cutaneous
adverse reactions (SCAR), which include the hypersensitiv-
ity syndrome, Stevens-Johnson syndrome, and toxic epi-
dermal necrolysis. Allopurinol-induced SCAR is strongly
associated with the HLA-B*58:01 allele. We sought to pre-
vent allopurinol-induced SCAR by using HLA-B*58:01
screening to prospectively identify subjects at risk for this
condition.
Methods
From 14 hospitals in Taiwan, we recruited 2037 candidate
subjects who had indication for allopurinol treatment but
had not taken allopurinol previously. We genotyped DNA
purified from the subjects’ PBMC to determine whether
they carried the HLA-B*58:01 allele. Those testing positive
for HLA-B*58:01 (20.57% of the total) were advised not to
take allopurinol and were given an alternative medication
or advised to continue taking their pre-study medication;
those testing negative (79.43%) were given allopurinol.
We interviewed the subjects by telephone once a week for
3 months to monitor them for symptoms. We used the
estimated historical incidence of SCAR for comparison.
Results
Mild, transient rash developed in 4.63% of subjects during
follow-up; more widespread rash was observed in 0.13% of
subjects, who were hospitalized. SCAR did not develop in
any of the HLA-B*58:01-negative subjects receiving allo-
purinol; this is in contrast to the 4 expected cases of
SCAR based on the estimated historical incidence of
allopurinol-induced SCAR (0.29%) (p value=0.0266;
Fisher’s two-tailed exact tests).
Conclusions
The identification of subjects carrying the HLA-B*58:01
allele and the avoidance of allopurinol therapy in these
subjects were strongly associated with a decreased inci-
dence of allopurinol-induced SCAR.
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